Original paper
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome
Abstract
Primary Sjögren syndrome (pSS) is a systemic autoimmune disease associated with dysregulated immune cells, with no efficient therapy. There is a need to study potential therapeutic approaches.To investigate the efficacy, safety, and immune response of low-dose interleukin 2 (LD-IL-2) in the treatment of pSS.A double-blind, placebo-controlled randomized clinical trial was conducted with a 2-group superiority design from June 2015 to August 2017....
Paper Details
Title
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome
Published Date
Nov 10, 2022
Journal
Volume
5
Issue
11
Pages
e2241451 - e2241451